Common Contracts
2 similar Notice of Exercise contracts by RespireRx Pharmaceuticals Inc.
WARRANT TO PURCHASE COMMON STOCK RespireRx Pharmaceuticals Inc.Notice of Exercise • October 14th, 2020 • RespireRx Pharmaceuticals Inc. • Pharmaceutical preparations • New York
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, FirstFire Global Opportunities Fund LLC or its permitted assigns (the “Holder”) is entitled, upon the terms and conditions hereof, and subject to the limitations on exercise hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. New York time on September 30, 2023 (the “Termination Date”) but not thereafter, to subscribe for and purchase from RespireRx Pharmaceuticals Inc., a Delaware corporation (the “Company”), 6,875,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of each share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
FORM OF CONVERTIBLE PROMISSORY NOTENotice of Exercise • December 17th, 2018 • RespireRx Pharmaceuticals Inc. • Pharmaceutical preparations • Delaware
FOR VALUE RECEIVED, RESPIRERX PHARMACEUTICALS INC., a Delaware corporation (“RespireRx” or the “Borrower”), with a mailing address at 126 Valley Road, Suite C, Glen Rock, New Jersey 07452, hereby promises to pay, unless previously converted, on the earlier of the business day following the first closing of the next exempt private securities offering of RespireRx, or, if not converted or repaid earlier, then on February 28, 2019 (the “Final Maturity Date”), and to the order of [___Name of lender__] (the “Lender”), with an address of [___Address of lender___], or at such other place as the holder hereof may designate in writing, the principal sum of [__Amount in words ] Dollars ($[_Amount in numbers__]), together with interest thereon at the interest rate as set forth herein (the “Loan”). The Lender’s books and records as to amounts due under this Note shall be conclusive absent manifest error.
